<ul>
<li>3 家小型生物科技公司在 2024 年有潜在突破</li>
</ul>
<p>Amylyx Pharmaceuticals（纳斯达克代码：AMLX）正在为其主要资产 AVEXITIDE 的关键第三阶段结果做准备，该资产用于治疗术后低血糖（PBH），LUCIDITY 试验的数据预计将在第三季度公布，联合首席执行官 Joshua Cohen 在美银年度医疗会议上表示。</p>
<p>获取 <strong>Amylyx Pharmaceuticals</strong> 的提醒：</p>
<p>在美银分析师 Jason Gerber 的主持下，Cohen 描述了即将发布的数据对公司短期前景的重要性，并表示该试验的设计与早期研究密切相似，早期研究显示对葡萄糖和胰岛素有统计学显著的影响，并减少了严重低血糖事件的发生。</p>
<ul>
<li>这些生物科技公司针对多种神经退行性疾病</li>
</ul>
<p>“我们对下个季度即将发布的第三阶段结果感到非常兴奋，” Cohen 说。“AVEXITIDE 是我们的主要资产，已经经历了五个先前的试验，所有试验均显示对葡萄糖和胰岛素有高度统计学显著的影响。”</p>
<h2>第三阶段试验旨在复制早期结果</h2>
<p>Cohen 表示，Amylyx 希望保持第三阶段 LUCIDITY 试验与早期的第二阶段和第二阶段 b 研究的一致性，包括相似的纳入和排除标准以及终点评估。第二阶段和第二阶段 b 研究要求患者在两周内至少发生两次严重低血糖事件，而第三阶段试验要求在三周内至少发生三次严重事件，保持每周大约一次的事件发生率阈值。</p>
<ul>
<li>Amylyx Pharmaceuticals 在成功推出药物后实现盈利</li>
</ul>
<p>关键的区别在于持续时间。先前的研究持续了四周，而 LUCIDITY 则持续 16 周。Cohen 表示，公司不认为更长的持续时间会降低治疗效果，并指出 Amylyx 没有看到如抗药物抗体等信号，这些信号可能表明随着时间的推移效果减弱。</p>
<p>Gerber 提到了 LUCIDITY 的统计假设，包括 90% 的能力检测 35% 的效果大小和 50% 的安慰剂反应。Cohen 表示，公司对研究的设计进行了保守估计，并不期望出现如此大的安慰剂反应，因为 PBH 患者已经采取措施避免严重低血糖。</p>
<p>“我们设定的目标是看到 35% 的相对率降低，但在第二阶段我们看到了 55%。在第二阶段 b 中，达到了 64%。” Cohen 说。“我们在所有统计假设中都采取了保守态度，部分原因是这是第一次进行第三阶段试验。”</p>
<h2>针对服务不足的 PBH 人群</h2>
<p>Cohen 将 PBH 描述为一种严重且服务不足的疾病，目前没有批准的治疗方法。他表示，患者经历反复的剧烈血糖下降，这可能发生在餐后，或因运动、压力或其他因素触发。这些事件可能导致头晕、失去意识、跌倒、车祸或癫痫，许多患者描述自己因无法驾驶或需要有人在身边以防失去意识而感到残疾。</p>
<p>他将 AVEXITIDE 与阿卡波糖进行对比，阿卡波糖是一种有时被非处方使用的α-葡萄糖苷酶抑制剂。Cohen 表示，阿卡波糖并未解决 Amylyx 认为的 PBH 的根本机制，并且可能导致胃肠道副作用，使患者难以坚持治疗。</p>
<p>根据 Cohen 的说法，PBH 涉及更快的营养物质转运，导致 GLP-1 反应过度。AVEXITIDE 是一种 GLP-1 拮抗剂，他表示该药物针对的是 Amylyx 认为的该疾病的核心机制。</p>
<p>“今天没有任何经过验证的治疗方法可以应对这些低血糖事件，” Cohen 说。“如果能够有一种治疗方法可能产生影响，正如我们所做的市场研究，治疗意向似乎很高。”</p>
<h2>NDA 准备和潜在的 2027 年上市</h2>
<p>如果第三阶段数据积极，Cohen 表示 Amylyx 打算尽快提交新药申请。他表示，公司已尽可能在数据发布之前完成申请的准备工作，以便在结果可用时进行整合，而不是在之后开始申请流程。</p>
<p>Cohen 表示，公司预计没有重大化学、生产和控制问题会延迟提交。Amylyx 已获得 AVEXITIDE 的突破性疗法认定，Cohen 表示公司预计与该认定相关的典型两个月提交期和六个月优先审查期。公司的目标是实现 2027 年上市。</p>
<p>关于监管互动，Cohen 表示 Amylyx 与 FDA 进行了 “正常业务” 讨论，并指出 LUCIDITY 的方案在试验开始前已提交并获得审查。他表示，该研究采用了安慰剂对照设计和一个公认的终点：低血糖。</p>
<h2>市场规模、准入和商业构建</h2>
<p>Cohen 表示，Amylyx 估计美国大约有 160,000 人患有 PBH。他表示，这一估计基于已发表的文献，包括对减肥手术队列的前瞻性研究，以及识别出接受减肥手术后出现无法解释的低血糖索赔的患者的索赔分析。</p>
<p>他表示，Amylyx 通过与治疗 PBH 患者的机构进行盲法市场研究进一步验证了其索赔工作，发现索赔估计通常与这些机构报告的患者数量一致。Cohen 还表示，Amylyx 预计 PBH 的 ICD-10 编码将在十月可用。</p>
<p>Cohen 表示，公司最初的商业重点将放在为 PBH 患者服务的专家中心和高流量机构，同时也教育医生和患者。他表示，一些患者可能需要 “重新激活”，如果他们之前因没有新的治疗选择而停止看内分泌科医生。</p>
<p>Amylyx 还在进行扩展使用计划，最初招募完成 LUCIDITY 或参与过之前 AVEXITIDE 试验的患者。Cohen 表示，许多患者已联系公司，并渴望重新接受治疗，尽管他表示扩展使用计划不应被视为市场规模的指标。</p>
<p>在谈到给药时，Cohen 表示之前试验中的依从性很强，Amylyx 不认为每日皮下注射会成为主要障碍，部分原因是 PBH 患者已经通过指尖采血监测血糖。</p>
<h2>管道更新和财务状况</h2>
<p>Cohen 表示，Amylyx 预计现金流将持续到 2028 年，并且其现金模型不包括收入，他将其描述为保守。他表示，公司预计在第三季度阶段 3 数据到来时将处于 “非常强劲的财务状况”。</p>
<p>该公司还在与 Gubra 合作开发一种长效 GLP-1 拮抗剂。Cohen 表示，该分子设计为至少每周一次，如果更好的话，但他警告说，直到临床测试开始，其人类药代动力学特征才会被了解。Amylyx 预计将在 2027 年提交一项新药研究申请。</p>
<p>Cohen 还讨论了 AMX0035 在沃尔夫拉姆综合症中的应用，这是一种影响美国约 3000 人的罕见单基因疾病。他表示，Amylyx 已展示 48 周的阶段 2 数据，显示在测量结果上总体稳定或改善，并计划展示 96 周的数据。该公司仍在与 FDA 合作设计潜在的阶段 3 试验及其主要终点。</p>
<p>虽然 Cohen 表示 Amylyx 将考虑沃尔夫拉姆项目的选项，但他强调公司的主要优先事项仍然是 AVEXITIDE 和即将到来的 LUCIDITY 结果。</p>
<h2>关于 Amylyx Pharmaceuticals NASDAQ: AMLX</h2>
<p>Amylyx Pharmaceuticals, Inc 是一家致力于开发罕见和严重神经疾病治疗的生物制药公司。公司成立于 2013 年，总部位于马萨诸塞州剑桥，专注于利用新颖的方法针对与神经退行性疾病相关的细胞通路。Amylyx 的研究平台以小分子疗法为中心，旨在保护神经元并支持患有目前缺乏或没有疾病修饰治疗选项的患者的细胞健康。</p>
<p>公司的主要产品 AMX0035 在美国以 Relyvrio 的商标销售。</p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Amylyx Pharmaceuticals 吗？</h2>
<p>在考虑投资 Amylyx Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Amylyx Pharmaceuticals 并不在名单上。</p>
<p>虽然 Amylyx Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AMLX

<p>Amylyx Pharmaceuticals 正在为其主要资产 AVEXITIDE 的关键第三阶段数据发布做准备，该药物用于治疗减肥手术后低血糖（PBH），预计数据将在 2023 年第三季度公布。联合首席执行官 Joshua Cohen 强调了该试验的设计，旨在复制早期研究显示的对葡萄糖和胰岛素的显著影响。如果结果积极，公司计划提交新药申请，争取在 2027 年推出。AVEXITIDE 针对 PBH 的潜在机制，解决这一没有批准疗法的严重疾病</p>

<ul>
<li>3 small-cap biotechs with potential breakthroughs in 2024</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家小型生物科技公司在 2024 年有潜在突破</li>
</ul>
</div><p>Amylyx Pharmaceuticals NASDAQ: AMLX is preparing for a pivotal Phase 3 readout for AVEXITIDE, its lead asset for post-bariatric hypoglycemia, or PBH, with data from the LUCIDITY trial expected in the third quarter, Co-Chief Executive Officer Joshua Cohen said at the BofA Annual Healthcare Conference.</p>
<div class="lb-trans"><p>Amylyx Pharmaceuticals（纳斯达克代码：AMLX）正在为其主要资产 AVEXITIDE 的关键第三阶段结果做准备，该资产用于治疗术后低血糖（PBH），LUCIDITY 试验的数据预计将在第三季度公布，联合首席执行官 Joshua Cohen 在美银年度医疗会议上表示。</p>
</div><p>Get <strong>Amylyx Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Amylyx Pharmaceuticals</strong> 的提醒：</p>
</div><p>In a discussion led by BofA analyst Jason Gerber, Cohen described the upcoming data as central to the company’s near-term outlook and said the trial was designed to closely mirror earlier studies that showed statistically significant effects on glucose and insulin, as well as reductions in severe hypoglycemic events.</p>
<div class="lb-trans"><p>在美银分析师 Jason Gerber 的主持下，Cohen 描述了即将发布的数据对公司短期前景的重要性，并表示该试验的设计与早期研究密切相似，早期研究显示对葡萄糖和胰岛素有统计学显著的影响，并减少了严重低血糖事件的发生。</p>
</div><ul>
<li>These biotechs targeting multiple neurodegenerative diseases</li>
</ul>
<div class="lb-trans"><ul>
<li>这些生物科技公司针对多种神经退行性疾病</li>
</ul>
</div><p>“We’re very excited about the Phase III readout expected next quarter,” Cohen said. “AVEXITIDE, our lead asset, has been through five prior trials, all of which showed highly statistically significant effects on glucose and insulin.”</p>
<div class="lb-trans"><p>“我们对下个季度即将发布的第三阶段结果感到非常兴奋，” Cohen 说。“AVEXITIDE 是我们的主要资产，已经经历了五个先前的试验，所有试验均显示对葡萄糖和胰岛素有高度统计学显著的影响。”</p>
</div><h2>Phase 3 Trial Designed to Replicate Earlier Results</h2>
<div class="lb-trans"><h2>第三阶段试验旨在复制早期结果</h2>
</div><p>Cohen said Amylyx sought to keep the Phase 3 LUCIDITY trial consistent with earlier Phase 2 and Phase 2b studies, including similar inclusion and exclusion criteria and endpoint assessment. The Phase 2 and Phase 2b studies required patients to have at least two severe hypoglycemic events over two weeks, while the Phase 3 trial requires at least three severe events over three weeks, maintaining an event-rate threshold of roughly one per week.</p>
<div class="lb-trans"><p>Cohen 表示，Amylyx 希望保持第三阶段 LUCIDITY 试验与早期的第二阶段和第二阶段 b 研究的一致性，包括相似的纳入和排除标准以及终点评估。第二阶段和第二阶段 b 研究要求患者在两周内至少发生两次严重低血糖事件，而第三阶段试验要求在三周内至少发生三次严重事件，保持每周大约一次的事件发生率阈值。</p>
</div><ul>
<li>Amylyx Pharmaceuticals Turns Profitable On Successful Drug Launch</li>
</ul>
<div class="lb-trans"><ul>
<li>Amylyx Pharmaceuticals 在成功推出药物后实现盈利</li>
</ul>
</div><p>The key difference is duration. The prior studies lasted four weeks, while LUCIDITY runs for 16 weeks. Cohen said the company does not expect the longer duration to reduce the treatment effect, noting that Amylyx has not seen signals such as anti-drug antibodies that would suggest attenuation over time.</p>
<div class="lb-trans"><p>关键的区别在于持续时间。先前的研究持续了四周，而 LUCIDITY 则持续 16 周。Cohen 表示，公司不认为更长的持续时间会降低治疗效果，并指出 Amylyx 没有看到如抗药物抗体等信号，这些信号可能表明随着时间的推移效果减弱。</p>
</div><p>Gerber cited statistical assumptions for LUCIDITY, including 90% power to detect a 35% effect size and a 50% placebo response. Cohen said the company powered the study conservatively and does not expect a placebo response of that magnitude, because patients with PBH are already taking steps to avoid severe hypoglycemia.</p>
<div class="lb-trans"><p>Gerber 提到了 LUCIDITY 的统计假设，包括 90% 的能力检测 35% 的效果大小和 50% 的安慰剂反应。Cohen 表示，公司对研究的设计进行了保守估计，并不期望出现如此大的安慰剂反应，因为 PBH 患者已经采取措施避免严重低血糖。</p>
</div><p>“We powered to see a 35% relative rate reduction, but in Phase II we saw 55%. In Phase II-B, a 64%,” Cohen said. “We were conservative in all the statistical assumptions, in part because this is the first Phase III.”</p>
<div class="lb-trans"><p>“我们设定的目标是看到 35% 的相对率降低，但在第二阶段我们看到了 55%。在第二阶段 b 中，达到了 64%。” Cohen 说。“我们在所有统计假设中都采取了保守态度，部分原因是这是第一次进行第三阶段试验。”</p>
</div><h2>Aiming at an Underserved PBH Population</h2>
<div class="lb-trans"><h2>针对服务不足的 PBH 人群</h2>
</div><p>Cohen characterized PBH as a severe and underserved condition with no approved therapies. He said patients experience recurrent, dramatic drops in blood sugar that may occur after meals or be triggered by exercise, stress or other factors. These events can cause dizziness, loss of consciousness, falls, car accidents or seizures, and many patients describe themselves as disabled because they cannot drive or need someone nearby in case they lose consciousness.</p>
<div class="lb-trans"><p>Cohen 将 PBH 描述为一种严重且服务不足的疾病，目前没有批准的治疗方法。他表示，患者经历反复的剧烈血糖下降，这可能发生在餐后，或因运动、压力或其他因素触发。这些事件可能导致头晕、失去意识、跌倒、车祸或癫痫，许多患者描述自己因无法驾驶或需要有人在身边以防失去意识而感到残疾。</p>
</div><p>He contrasted AVEXITIDE with acarbose, an alpha-glucosidase inhibitor sometimes used off-label. Cohen said acarbose does not address what Amylyx views as the underlying mechanism of PBH and can cause gastrointestinal side effects that make it difficult for patients to remain on therapy.</p>
<div class="lb-trans"><p>他将 AVEXITIDE 与阿卡波糖进行对比，阿卡波糖是一种有时被非处方使用的α-葡萄糖苷酶抑制剂。Cohen 表示，阿卡波糖并未解决 Amylyx 认为的 PBH 的根本机制，并且可能导致胃肠道副作用，使患者难以坚持治疗。</p>
</div><p>According to Cohen, PBH involves faster nutrient transit that drives an exaggerated GLP-1 response. AVEXITIDE is a GLP-1 antagonist, which he said targets what Amylyx believes is the core mechanism of the condition.</p>
<div class="lb-trans"><p>根据 Cohen 的说法，PBH 涉及更快的营养物质转运，导致 GLP-1 反应过度。AVEXITIDE 是一种 GLP-1 拮抗剂，他表示该药物针对的是 Amylyx 认为的该疾病的核心机制。</p>
</div><p>“There’s nothing available today that’s been proven to do anything to these hypoglycemic events,” Cohen said. “To potentially have a therapeutic that could impact that, as we’ve done market research, the intent to treat does seem high.”</p>
<div class="lb-trans"><p>“今天没有任何经过验证的治疗方法可以应对这些低血糖事件，” Cohen 说。“如果能够有一种治疗方法可能产生影响，正如我们所做的市场研究，治疗意向似乎很高。”</p>
</div><h2>NDA Preparation and Potential 2027 Launch</h2>
<div class="lb-trans"><h2>NDA 准备和潜在的 2027 年上市</h2>
</div><p>If the Phase 3 data are positive, Cohen said Amylyx intends to submit a new drug application as quickly as possible. He said the company has tried to complete as much of the application as possible ahead of the data readout so that it can incorporate results once available, rather than begin the filing process afterward.</p>
<div class="lb-trans"><p>如果第三阶段数据积极，Cohen 表示 Amylyx 打算尽快提交新药申请。他表示，公司已尽可能在数据发布之前完成申请的准备工作，以便在结果可用时进行整合，而不是在之后开始申请流程。</p>
</div><p>Cohen said there is no major chemistry, manufacturing and controls issue that the company expects would delay submission. Amylyx has Breakthrough Therapy designation for AVEXITIDE, and Cohen said the company expects the typical two-month filing period and six-month priority review associated with that designation. The company’s goal is to enable a 2027 launch.</p>
<div class="lb-trans"><p>Cohen 表示，公司预计没有重大化学、生产和控制问题会延迟提交。Amylyx 已获得 AVEXITIDE 的突破性疗法认定，Cohen 表示公司预计与该认定相关的典型两个月提交期和六个月优先审查期。公司的目标是实现 2027 年上市。</p>
</div><p>On regulatory interactions, Cohen said Amylyx has had “business as usual” discussions with the FDA and noted that the LUCIDITY protocol was submitted and reviewed before the trial began. He said the study uses a placebo-controlled design and a well-established endpoint: hypoglycemia.</p>
<div class="lb-trans"><p>关于监管互动，Cohen 表示 Amylyx 与 FDA 进行了 “正常业务” 讨论，并指出 LUCIDITY 的方案在试验开始前已提交并获得审查。他表示，该研究采用了安慰剂对照设计和一个公认的终点：低血糖。</p>
</div><h2>Market Size, Access and Commercial Build</h2>
<div class="lb-trans"><h2>市场规模、准入和商业构建</h2>
</div><p>Cohen said Amylyx estimates there are about 160,000 people in the U.S. with PBH. He said that estimate is based on published literature, including prospective studies of bariatric surgery cohorts, as well as claims analyses identifying patients with bariatric surgery and subsequent unexplained hypoglycemia claims.</p>
<div class="lb-trans"><p>Cohen 表示，Amylyx 估计美国大约有 160,000 人患有 PBH。他表示，这一估计基于已发表的文献，包括对减肥手术队列的前瞻性研究，以及识别出接受减肥手术后出现无法解释的低血糖索赔的患者的索赔分析。</p>
</div><p>He said Amylyx further validated its claims work through blinded market research with sites that treat PBH patients, finding that claims estimates were generally aligned with the number of patients those sites reported seeing. Cohen also said Amylyx expects an ICD-10 code for PBH to become available in October.</p>
<div class="lb-trans"><p>他表示，Amylyx 通过与治疗 PBH 患者的机构进行盲法市场研究进一步验证了其索赔工作，发现索赔估计通常与这些机构报告的患者数量一致。Cohen 还表示，Amylyx 预计 PBH 的 ICD-10 编码将在十月可用。</p>
</div><p>Cohen said the company’s initial commercial focus would be on expert centers and high-volume sites serving PBH patients, while also educating physicians and patients. Some patients, he said, may need to be “reactivated” if they previously stopped seeing endocrinologists because there were no new treatment options available.</p>
<div class="lb-trans"><p>Cohen 表示，公司最初的商业重点将放在为 PBH 患者服务的专家中心和高流量机构，同时也教育医生和患者。他表示，一些患者可能需要 “重新激活”，如果他们之前因没有新的治疗选择而停止看内分泌科医生。</p>
</div><p>Amylyx is also running an expanded access program, initially enrolling patients who completed LUCIDITY or participated in prior AVEXITIDE trials. Cohen said many of those patients have contacted the company and are eager to return to therapy, though he said the expanded access program should not be viewed as a market-size indicator.</p>
<div class="lb-trans"><p>Amylyx 还在进行扩展使用计划，最初招募完成 LUCIDITY 或参与过之前 AVEXITIDE 试验的患者。Cohen 表示，许多患者已联系公司，并渴望重新接受治疗，尽管他表示扩展使用计划不应被视为市场规模的指标。</p>
</div><p>Discussing administration, Cohen said adherence in prior trials was strong and that Amylyx does not expect daily subcutaneous injection to be a major barrier, in part because patients with PBH already monitor blood glucose through finger sticks.</p>
<div class="lb-trans"><p>在谈到给药时，Cohen 表示之前试验中的依从性很强，Amylyx 不认为每日皮下注射会成为主要障碍，部分原因是 PBH 患者已经通过指尖采血监测血糖。</p>
</div><h2>Pipeline Updates and Financial Position</h2>
<div class="lb-trans"><h2>管道更新和财务状况</h2>
</div><p>Cohen said Amylyx has guided to a cash runway into 2028 and that its cash modeling does not include revenue, which he characterized as conservative. He said the company expects to be in a “very strong financial position” when Phase 3 data arrive in the third quarter.</p>
<div class="lb-trans"><p>Cohen 表示，Amylyx 预计现金流将持续到 2028 年，并且其现金模型不包括收入，他将其描述为保守。他表示，公司预计在第三季度阶段 3 数据到来时将处于 “非常强劲的财务状况”。</p>
</div><p>The company is also working on a longer-acting GLP-1 antagonist developed with Gubra. Cohen said the molecule was designed to be at least once-weekly, if not better, but cautioned that its human pharmacokinetic profile will not be known until clinical testing begins. Amylyx expects to submit an investigational new drug application in 2027.</p>
<div class="lb-trans"><p>该公司还在与 Gubra 合作开发一种长效 GLP-1 拮抗剂。Cohen 表示，该分子设计为至少每周一次，如果更好的话，但他警告说，直到临床测试开始，其人类药代动力学特征才会被了解。Amylyx 预计将在 2027 年提交一项新药研究申请。</p>
</div><p>Cohen also discussed AMX0035 in Wolfram syndrome, a rare monogenic disease affecting an estimated 3,000 people in the U.S. He said Amylyx has presented 48-week Phase 2 data showing general stabilization or improvement across measured outcomes and plans to present 96-week data. The company is still working with the FDA on the design and primary endpoint for a potential Phase 3 trial.</p>
<div class="lb-trans"><p>Cohen 还讨论了 AMX0035 在沃尔夫拉姆综合症中的应用，这是一种影响美国约 3000 人的罕见单基因疾病。他表示，Amylyx 已展示 48 周的阶段 2 数据，显示在测量结果上总体稳定或改善，并计划展示 96 周的数据。该公司仍在与 FDA 合作设计潜在的阶段 3 试验及其主要终点。</p>
</div><p>While Cohen said Amylyx will consider its options for the Wolfram program, he emphasized that the company’s main priority remains AVEXITIDE and the upcoming LUCIDITY readout.</p>
<div class="lb-trans"><p>虽然 Cohen 表示 Amylyx 将考虑沃尔夫拉姆项目的选项，但他强调公司的主要优先事项仍然是 AVEXITIDE 和即将到来的 LUCIDITY 结果。</p>
</div><h2>About Amylyx Pharmaceuticals NASDAQ: AMLX</h2>
<div class="lb-trans"><h2>关于 Amylyx Pharmaceuticals NASDAQ: AMLX</h2>
</div><p>Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.</p>
<div class="lb-trans"><p>Amylyx Pharmaceuticals, Inc 是一家致力于开发罕见和严重神经疾病治疗的生物制药公司。公司成立于 2013 年，总部位于马萨诸塞州剑桥，专注于利用新颖的方法针对与神经退行性疾病相关的细胞通路。Amylyx 的研究平台以小分子疗法为中心，旨在保护神经元并支持患有目前缺乏或没有疾病修饰治疗选项的患者的细胞健康。</p>
</div><p>The company's lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.</p>
<div class="lb-trans"><p>公司的主要产品 AMX0035 在美国以 Relyvrio 的商标销售。</p>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amylyx Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Amylyx Pharmaceuticals 吗？</h2>
</div><p>Before you consider Amylyx Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Amylyx Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amylyx Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Amylyx Pharmaceuticals 并不在名单上。</p>
</div><p>While Amylyx Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Amylyx Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus

Market Beat

Amylyx Pharmaceuticals

美国银行

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

随着 2027 年推出逐渐成为焦点，Amylyx Pharmaceuticals 关注第三阶段 AVEXITIDE 的结果